We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
CALL
Zymeworks
ZYME
$1.67B
$17.7M 0.78%
375,200
-124,800
-25% -$5.8M
CRSP icon
27
PUT
CRISPR Therapeutics
CRSP
$4.77B
$17.7M 0.78%
115,300
– –
AZN icon
28
CALL
AstraZeneca
AZN
$266B
$17.5M 0.77%
+175,000
New +$18.5M
GILD icon
29
CALL
Gilead Sciences
GILD
$163B
$17.5M 0.77%
+300,000
New +$18.1M
ZGNX
30
CALL
DELISTED
Zogenix, Inc.
ZGNX
$17.3M 0.76%
867,400
-32,600
-4% -$666K
MORF
31
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$17.3M 0.76%
+516,763
New +$15.3M
LLY icon
32
CALL
Eli Lilly
LLY
$1.03T
$16.9M 0.74%
+100,000
New +$14.9M
IONS icon
33
CALL
Ionis Pharmaceuticals
IONS
$8.85B
$16.4M 0.72%
+290,000
New +$14.5M
TARA icon
34
Protara Therapeutics
TARA
$227M
$15.7M 0.69%
649,542
-72,901
-10% -$1.57M
ARWR icon
35
PUT
Arrowhead Research
ARWR
$12.3B
$15.3M 0.68%
+200,000
New +$12.8M
ASND icon
36
Ascendis Pharma A/S
ASND
$16.5B
$14.5M 0.64%
+87,090
New +$14.4M
PRTA icon
37
Prothena Corp
PRTA
$440M
$14.3M 0.63%
+1,186,700
New +$14M
OCUL icon
38
Ocular Therapeutix
OCUL
$1.85B
$14.2M 0.62%
684,573
-1,031,720
-60% -$15.3M
BPMC
39
PUT
DELISTED
Blueprint Medicines
BPMC
$13.5M 0.59%
+120,000
New +$12.6M
STRO icon
40
Sutro Biopharma
STRO
$411M
$13.4M 0.59%
61,536
+12,736
+26% +$2.11M
CRIS icon
41
Curis
CRIS
$9.67M
$12.9M 0.57%
+3,938
New +$4.73M
XLRN
42
PUT
DELISTED
Acceleron Pharma
XLRN
$12.8M 0.56%
+100,000
New +$11.7M
MIST icon
43
Milestone Pharmaceuticals
MIST
$143M
$12.3M 0.54%
1,836,545
+93,000
+5% +$623K
KRTX
44
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.2M 0.54%
+120,000
New +$11.1M
VINC
45
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$11.3M 0.5%
26,934
+14,846
+123% +$4.68M
KYNB
46
CALL
Kyntra Bio
KYNB
$27.5M
$11.1M 0.49%
12,000
+4,000
+50% +$4.2M
MRTX
47
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11M 0.48%
+50,000
New +$10.8M
CYRX icon
48
CALL
CryoPort
CYRX
$773M
$11M 0.48%
250,000
-22,900
-8% -$1.09M
IMVT icon
49
Immunovant
IMVT
$8.11B
$10.9M 0.48%
235,587
-86,300
-27% -$3.99M
UTHR icon
50
CALL
United Therapeutics
UTHR
$26.2B
$10.5M 0.46%
+69,300
New +$9.09M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.